Novo Nordisk on Friday forecast its sales growth would slow by about 3% in 2022 because of lower prices and a drop in insulin sales volumes in China, denting the Danish diabetes drug maker's share price. The forecast comes after Novo received results from China's Volume Based Procurement (VBP) tender, which covers insulin sold at Chinese hospitals. "Novo Nordisk currently expects an estimated negative impact on global sales growth of around 3% in 2022 as a result of reduced prices and reduced volumes of insulin sold in China," it said in a statement.
The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.
Novo Nordisk (NVO) inks agreement to acquire Dicerna for $3.3 billion. The company is looking to boost its RNAi research platform with this acquisition.